AMENDMENTS TO THE CLAIMS:

The following listing of the claims replaces all prior versions or listings:

1. (Currently Amended) A pharmaceutical composition, comprising:

at least one pharmaceutically active ingredient;

poly(ethylene sebacate); and

wherein said pharmaceutical composition ~~is in the form of different~~ comprises one or more solid or liquid drug delivery systems, wherein said one or more solid or liquid drug delivery systems comprise one or more of the following structures: drug loaded microparticles, microcapsules, nanoparticles, non-stent ~~molded~~ implants, ~~coated~~ granules, films, ~~coated~~ tablets, ophthalmic inserts, fibers, ligatures or sutures.

2. (Currently amended) The pharmaceutical composition as claimed in claim 1 wherein molecular weight of said poly(ethylene sebacate) is in the range of approximately 3,000 to 30,000.

3. (Currently amended) The pharmaceutical composition as claimed in claim 1, wherein said pharmaceutically active ingredient comprises anti-hypertensives, cardiovascular agents, analgesics, steroids, physiologically active peptides and/or proteins, anti-cancer agents, antibiotics, fibrinolytics, anti-inflammatory agents, expectorants, muscle relaxants, epilepsy remedies, anti-ulcerative agents, anti-hyperchondriac agents, anti-allergic agents, diuretics diabetes curatives, hyperlipidemic remedies, anticoagulants, hemolytic agents, anti tubercular agents, hormones, anesthetic antagonists, osteoclastic

suppressants, osteogenic promotives, angiogenesis suppressors, mydriatics, myotics, or glaucoma therapy, or any combinations thereof, including ~~and/or~~ mixtures ~~thereof~~.

4. (Currently amended) The pharmaceutical composition as claimed in claim 1, wherein said pharmaceutically active ingredient to poly(ethylene sebacate) ratio is in the range from approximately 95:5 to 1:99.

5. (Cancelled)

6. (Cancelled)

7. (Currently amended) The pharmaceutical composition as claimed in claim 1, wherein said one or more solid or liquid drug delivery systems comprise coated granules, prepared by coating the granules with approximately 1-5% solution of said poly(ethylene sebacate) in a suitable solvent.

8. (Previously presented) The pharmaceutical composition as claimed in claim 1, wherein said one or more solid or liquid drug delivery systems comprise injectable microparticles suitable for sub-cutaneous, intra-muscular, intravenous or periodontal administration.

9. (Cancelled)

10. (Currently amended) The pharmaceutical composition as claimed in claim 1, wherein said one or more solid or liquid drug delivery systems comprise microparticles ~~and/or~~ or nanoparticles dispersed in a gel formulation capable of periodontal administration.

11. (Previously presented) The pharmaceutical composition as claimed in claim 1, wherein said one or more solid or liquid drug delivery systems comprise film.

12. (Previously presented) The pharmaceutical composition as claimed in claim 1, wherein said microcapsules comprise sustained release microcapsules.

13. (Previously presented) The pharmaceutical composition as claimed in claim 12, wherein said microcapsules are produced in an oil/water suspension system, in which the drug is embedded within the polymer microparticles forming the oil phase, and stabilizing agents for the microparticles forming an aqueous phase.

14. (Currently amended) The pharmaceutical composition as claimed in claim 13, wherein the stabilizing agents comprise polyvinyl alcohol, polyvinyl pyrrolidone, alginate, gelatin, methyl cellulose, polyoxyethylene derivatives of sorbitan fatty esters ~~and/or~~ or polyoxyethylene fatty ethers.

15. (Currently amended) The pharmaceutical composition as claimed in claim 1, wherein a particle size of said nanoparticles is in the range of approximately 10 nanometers to 500 nanometers.

16. (Previously presented) The pharmaceutical composition as claimed in claim 1, wherein said one or more solid or liquid drug delivery systems comprise lipase capable of modifying release of said pharmaceutically active ingredient.

17. (Currently amended) The pharmaceutical composition as claimed in claim 1, wherein said pharmaceutical composition is capable of being administered by ~~either~~ oral, ophthalmic, parenteral, mucosal or transdermal route.

18. (Cancelled)

19. (Currently amended) The pharmaceutical composition of claim 1, wherein said non-stent ~~molded~~ implant is formed by melt molding.

20. (Previously presented) A pharmaceutical composition, comprising:

at least one pharmaceutically active ingredient;

poly(ethylene sebacate); and

wherein said pharmaceutical composition is in the form of one or more solid or liquid drug delivery systems, wherein said one or more solid or liquid drug delivery systems comprise at least drug loaded microparticles produced by preparation of an oil/water suspension system utilizing polymer microparticles .

21. (Previously presented) The pharmaceutical composition as claimed in claim 20, wherein a drug is embedded within the polymer microparticles forming an oil phase of the

oil/water suspension system, and stabilizing agents for the microparticles forming an aqueous phase.

22. (New) The pharmaceutical composition as claimed in claim 1, wherein said poly(ethylene sebacate) is capable of releasing said water-insoluble acid without an addition of an external lipase to said at least one pharmaceutically active ingredient.

23. (New) The pharmaceutical composition as claimed in claim 1, wherein said pharmaceutical composition comprises sebacic acid formed during hydrolysis of said poly(ethylene sebacate).